Compare GREE & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GREE | SCNX |
|---|---|---|
| Founded | 1937 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Other Pharmaceuticals |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 18.4M |
| IPO Year | N/A | 2020 |
| Metric | GREE | SCNX |
|---|---|---|
| Price | $1.22 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 129.8K | ★ 604.9K |
| Earning Date | 03-30-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,115,000.00 | $653,391.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 207.88 |
| 52 Week Low | $0.58 | $0.42 |
| 52 Week High | $2.42 | $3.61 |
| Indicator | GREE | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 32.32 |
| Support Level | $1.09 | $0.42 |
| Resistance Level | $1.35 | $0.48 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 47.08 | 7.39 |
Greenidge Generation Holdings Inc owns and operates a vertically integrated cryptocurrency data center. Company operates in three segments: Crypto Mining, Datacenter Hosting, Power and Capacity. The company owns and operates facilities at two locations: the Torrey, New York, and Spartanburg, South Carolina. The cryptocurrency data center operations generate revenue in the form of bitcoin by earning bitcoin as rewards and transaction fees for supporting the bitcoin network with application-specific integrated circuit computers (ASICs or miners) owned or leased by the company.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.